Long-Term Survival of Over 6 Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report.

Clin Drug Investig

Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, 106 Zhongshan Er Rd, Guangzhou, 510080, China.

Published: May 2021

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149342	PMC
http://dx.doi.org/10.1007/s40261-021-01025-6	DOI Listing

Publication Analysis

long-term survival

survival 6 years

6 years afatinib

afatinib sequential

sequential treatment

treatment patient

patient egfr

egfr mutation-positive

mutation-positive non-small

non-small cell

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!